Form 4: Edwards Lifesciences Executive Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Filing
Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, executed stock options and sold shares according to a pre-arranged Rule 10b5-1 trading plan.
Summary
- On February 13, 2025, Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, exercised options to acquire 500 shares of common stock at a price of $45.2767.
- Simultaneously, Lippis sold 500 shares of common stock at a price of $76.34.
- These transactions were executed under a pre-existing Rule 10b5-1 trading plan adopted on December 11, 2023.
- Following these transactions, Lippis directly owns 23,189.0651 shares of Edwards Lifesciences common stock and 1,030 employee stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reflects routine transactions under a pre-arranged trading plan.
Industry Context
This filing is a routine disclosure of insider transactions and doesn't necessarily indicate a broader trend within the medical device industry.
Key Dates
| Date | Description |
|---|---|
| 12/11/2023 | Date of adoption of Rule 10b5-1 trading plan |
| 05/17/2019 | Employee Stock Option Date Exercisable |
| 02/13/2025 | Date of transaction (exercise of options and sale of shares) |
| 05/16/2025 | Employee Stock Option Expiration Date |
Keywords
Form 4, Edwards Lifesciences, Daniel J. Lippis, Stock Options, Share Sale, Rule 10b5-1, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.